Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension

被引:210
作者
Tongers, Joern
Schwerdtfeger, Ben
Klein, Gunnar
Kempf, Tibor
Schaefer, Arnd
Knapp, Julia-Marie
Niehaus, Michael
Korte, Thomas
Hoeper, Marius M.
机构
[1] Hannover Med Sch, Dept Resp Med, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Cardiol & Angiol, D-30625 Hannover, Germany
关键词
D O I
10.1016/j.ahj.2006.09.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background In patients with severe pulmonary hypertension (PH), right ventricular function is a main determinant of clinical stability and outcome. Supraventricular tachyarrhythmias (SVTs) may compromise cardiac function and threaten prognosis in patients with PH, but the incidence and clinical relevance of SVTs in PH and chronic right ventricular failure have not been evaluated. Methods In a 6-year retrospective single-center analysis, 23 1 consecutive patients followed for pulmonary arterial hypertension, or inoperable chronic thromboembolic PH were studied for SVTs. Analysis included incidence, clinical consequences, treatment, and outcome. Results Thirty-one episodes of SVT were observed in 27 of 231 patients (cumulative incidence 11.7%, annual risk 2.8% per patient), including atrial flutter (n = 15), atrial fibrillation (n = 13), and AV nodal reentry tachycardia (n = 3). Supraventricular tachyarrhythmia onset was almost invariably associated with marked clinical deterioration and right. ventricular failure (84% of SVT episodes). Outcome was strongly associated with the type of SVT and restoration of sinus rhythm. During follow-up, cumulative mortality was low (6.3%, follow-up 26 23 months) when sinus rhythm was restored (all cases of AV nodal reentry tachycardia and atrial flutter). In contrast, 9 of I I patients with sustained atrial fibrillation died from right ventricular failure (cumulative mortality 82%, follow-up 11 8 months). Conclusions In patients with PH, SVTs constitute a relevant problem, often resulting in clinical deterioration. Sustained atrial fibrillation may be associated with a high risk of death from right ventricular failure.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 48 条
[1]   ATRIOVENTRICULAR NODAL REENTRY - CLINICAL, ELECTROPHYSIOLOGICAL, AND THERAPEUTIC CONSIDERATIONS [J].
AKHTAR, M ;
JAZAYERI, MR ;
SRA, J ;
BLANCK, Z ;
DESHPANDE, S ;
DHALA, A .
CIRCULATION, 1993, 88 (01) :282-295
[2]  
[Anonymous], 2001, CIRCULATION, V104, P2118
[3]   Primary pulmonary hypertension - A vascular biology and translational research "work in progress" [J].
Archer, S ;
Rich, S .
CIRCULATION, 2000, 102 (22) :2781-2791
[4]   Prostanoid therapy for pulmonary arterial hypertension [J].
Badesch, DB ;
McLaughlin, VV ;
Delcroix, M ;
Vizza, CD ;
Olschewski, H ;
Sitbon, O ;
Barst, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :56S-61S
[5]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[6]   Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].
Badesch, DB ;
Abman, SH ;
Ahearn, GS ;
Barst, RJ ;
McCrory, DC ;
Simonneau, G ;
McLaughlin, VV .
CHEST, 2004, 126 (01) :35S-62S
[7]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[8]   Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].
Barst, RJ ;
Rich, S ;
Widlitz, A ;
Horn, EM ;
McLaughlin, V ;
McFarlin, J .
CHEST, 2002, 121 (06) :1860-1868
[9]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[10]   Beraprost therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
McLaughlin, V ;
Tapson, V ;
Oudiz, R ;
Shapiro, S ;
Robbins, IM ;
Channick, R ;
Badesch, D ;
Rayburn, BK ;
Flinchbaugh, R ;
Sigman, J ;
Arneson, C ;
Jeffs, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125